Asparaginase-Phage P22 Nanoreactors: Toward a Biobetter Development for Acute Lymphoblastic Leukemia Treatment

• 主要な著者: Cristina Díaz-Barriga (著者), Francisca Villanueva-Flores (著者), Katrin Quester (著者), Andrés Zárate-Romero (著者), Ruben Dario Cadena-Nava (著者), Alejandro Huerta-Saquero (著者)
• フォーマット: 図書
• 出版事項: MDPI AG, 2021-04-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Asparaginase (ASNase) is a biopharmaceutical for Acute Lymphoblastic Leukemia (ALL) treatment. However, it shows undesirable side effects such as short lifetimes, susceptibility to proteases, and immunogenicity. Here, ASNase encapsidation was genetically directed in bacteriophage P22-based virus-lik...